VATER-like Syndrome with Pulmonary Hypertension

VATER-like syndrome refers to a pattern of birth differences that tend to appear together. Doctors first used the shorter name VATER for: Vertebral defects, Anal atresia, Tracheo-Esophageal fistula (TEF) with esophageal atresia, and Renal or Radial (limb) anomalies. Later, the acronym was expanded to VACTERL to add Cardiac (heart) defects and Limb anomalies. Not every child has all features. A clinical diagnosis is usually made when at least three of these core features are present and no single genetic syndrome better explains the findings. Because a single common cause is not proven, clinicians call it an association rather than a classic syndrome. PubMed+2orpha.net+2

Pulmonary hypertension (PH) means the blood pressure in the lung arteries is abnormally high. Today, PH is defined as a mean pulmonary artery pressure (mPAP) > 20 mmHg at rest, confirmed by right-heart catheterization, which is considered the gold standard test. For pulmonary arterial hypertension (PAH)—the pre-capillary form—doctors also look for pulmonary vascular resistance (PVR) > 2 Wood units and a pulmonary wedge pressure ≤ 15 mmHg to show the problem is not from left-sided heart disease. American College of Cardiology+2publications.ersnet.org+2

VATER-like syndrome with pulmonary hypertension means a person has birth defects that fit the VATER/VACTERL pattern (for example, heart or airway problems) and also has high blood pressure in the lung arteries. The lung arteries become tight and stiff, which forces the right side of the heart to work too hard. Over time, this can cause shortness of breath, poor exercise tolerance, fainting, leg swelling, and heart strain. Doctors confirm the PH type (especially PAH) with tests and then use a step-by-step plan based on risk: supportive measures, one or more PAH-targeted drugs, and, in advanced cases, specialized procedures or transplant. Care should be led by a pulmonary hypertension center, because treatment choices depend on the person’s anatomy (for example, which cardiac or airway defects are present) and ongoing risk assessment. publications.ersnet.org+3MedlinePlus+3PubMed+3

When a person has VATER/VACTERL-like features plus pulmonary hypertension, the PH most often links to an underlying heart defect (CHD), abnormal lung or airway development, recurrent lung infections, or chronic hypoxia from airway or feeding problems (for example, tracheo-esophageal fistula with aspiration). Case reports also describe complex airway malformations in VACTERL that can worsen lung blood pressure over time. ahajournals.org+1

---

Other names

• VATER association (original acronym)

• VACTERL association (expanded acronym)

• VATER/VACTERL spectrum or VACTERL-like phenotype (used when features are partial or overlapping)
  These names reflect the same clinical concept: a non-random cluster of malformations without one proven single cause. PubMed+1

---

Types

1. Classic VACTERL association – at least three core features (for example, anal atresia, TEF, and a heart defect). PubMed

2. VATER-like / VACTERL-like – some features are present, but the full criteria may not be met, or findings are borderline. Clinicians may still use the term to guide evaluation for hidden defects. Wiley Online Library

3. VACTERL with dominant organ involvement – one area (e.g., heart or kidneys) is the main problem, but others are milder. This is common in real life. PubMed

4. VACTERL overlap with specific syndromes – sometimes features overlap with conditions like CHARGE, 22q11 deletion, Townes-Brocks, or others; careful genetics workup is needed to rule these out. PMC

5. VACTERL with airway anomalies – rare patterns such as bridging bronchus or severe airway malacia; these can lead to recurrent infections and contribute to PH risk. PMC

6. VACTERL with pulmonary hypertension – the focus here; PH often relates to a shunt lesion (e.g., VSD, PDA) or chronic lung/airway issues that raise pressure in lung arteries. ahajournals.org

---

Causes

These are factors and mechanisms linked to the VATER/VACTERL pattern and/or to pulmonary hypertension in this setting. Some are associations rather than proven causes; clinicians consider them when evaluating a patient.

1. Multifactorial developmental disruption during early embryogenesis – a broad, likely explanation; multiple small hits during very early development can affect mesoderm-derived structures (spine, heart, kidneys, limbs, TEF). PubMed

2. Candidate gene variants (e.g., ZIC3, FOXF1, HOXD13, PTEN, FGF8, TRAP1, LPP) – reported in subsets; not a single universal gene, but these pathways may influence the VACTERL phenotype. PMC+1

3. FOXF1/FOX cluster disturbances with pulmonary involvement – FOXF1 is important for lung vasculature and foregut development; disruptions have been linked to VACTERL-like features and pulmonary problems. PMC

4. Mitochondrial dysfunction (reported cases) – rare reports suggest mitochondrial issues in some VACTERL-like patients; evidence remains limited. PMC

5. Maternal pregestational diabetes (possible association) – some studies and reviews suggest increased risk of VACTERL features with first-trimester exposure, though causality is not certain. PubMed

6. Assisted reproductive technology (ART) – large registry data found invasive ART associated with higher odds of VACTERL in offspring. Wiley Online Library

7. Maternal overweight/obesity and primiparity – reported as risk factors in a case-control study. PMC

8. Maternal smoking and lack of folic acid supplementation – identified as risks in population analyses. PMC

9. Teratogen exposure (animal model with adriamycin) – experimental rat models show VACTERL-like malformations after certain drugs; informs mechanisms but not routine human causation. PMC

10. Chromosomal or syndromic mimics – conditions like 22q11.2 deletion can look similar; they are not causes of VACTERL but alternative explanations that must be ruled out. PMC

11. Cardiac left-to-right shunts (e.g., VSD, PDA) causing high flow to lung arteries → vascular remodeling → pulmonary hypertension if unrepaired. ahajournals.org

12. Complex congenital heart disease (e.g., Tetralogy of Fallot with pulmonary outflow issues) – cyanosis and altered flow can contribute to PH or complex hemodynamics. European Society of Medicine –

13. Chronic hypoxia from airway anomalies (e.g., tracheomalacia, bridging bronchus) – low oxygen triggers vasoconstriction and vascular changes in lung arteries. PMC

14. Recurrent aspiration from TEF/esophageal dysmotility – micro-aspiration injures lungs, causing inflammation and higher pulmonary pressures over time. Children’s Hospital of Philadelphia

15. Abnormal lung development (e.g., bronchopulmonary foregut malformations such as “esophageal lung”) – rare malformations associated with VACTERL can cause severe lung disease and PH. MSJ Online

16. Sleep-disordered breathing in craniofacial or airway variants – intermittent hypoxia may raise pulmonary pressures; clinicians screen for this in complex airway phenotypes. (Mechanistic inference consistent with PH literature.) cdt.amegroups.org

17. Post-surgical complications – residual shunts, scarring, or airway stenosis after repairs may maintain high pulmonary pressures. ahajournals.org

18. Chronic lung disease from infections – repeated pneumonias in infancy can injure lungs and elevate PVR (pulmonary vascular resistance). cdt.amegroups.org

19. High altitude exposure (later in life) – hypoxia at altitude can worsen PH in those with underlying vulnerabilities. cdt.amegroups.org

20. Idiopathic or multifactorial PAH despite repair – even after cardiac repairs, some patients develop or keep PH due to persistent small-vessel disease. ahajournals.org

---

Symptoms

Symptoms vary with which VATER/VACTERL features are present and whether pulmonary hypertension has developed. A newborn or child may show several of these at different times.

1. Breathing fast or hard—especially with feeds or crying—suggests extra work for the lungs. PH and airway issues both cause this. ahajournals.org

2. Blue lips or skin (cyanosis)—from low oxygen or heart defects. Children’s Hospital of Philadelphia

3. Poor feeding and slow weight gain—common in TEF/EA repair patients and in babies with PH because feeding is tiring. Children’s Hospital of Philadelphia

4. Recurrent cough, choking, or pneumonia—can come from TEF, aspiration, or airway malacia. PMC

5. No stool after birth or severe constipation—points to anorectal malformation. Children’s Hospital of Philadelphia

6. Abnormal urine stream or kidney troubles—from renal/urinary anomalies. orpha.net

7. Spinal curvature or back problems—from vertebral defects. orpha.net

8. Limb differences—such as a small or missing thumb or forearm changes. Children’s Hospital of Philadelphia

9. Heart murmur, fast heartbeat, or easy tiring—possible heart defect or PH strain. Children’s Hospital of Philadelphia

10. Sweating with feeds—a subtle sign of heart strain in infants. ahajournals.org

11. Swollen legs or belly (later)—right-sided heart failure from long-standing PH. ahajournals.org

12. Dizziness or fainting (later child/teen)—reduced blood flow from advanced PH. ahajournals.org

13. Whooping or noisy breathing—airway malacia or stenosis. PMC

14. Frequent respiratory infections—due to airway anomalies or aspiration. PMC

15. Delayed milestones mainly from medical fragility, not intelligence—many children have normal intelligence but need time to recover from surgeries and illnesses. Children’s Hospital of Philadelphia

---

Diagnostic tests

A) Physical examination (bedside checks)

1. General newborn exam – doctors check breathing effort, color, feeding, rib retractions, clubbing (later sign), and growth. This helps judge lung and heart stress right away. Children’s Hospital of Philadelphia

2. Cardiac auscultation and pulses – murmurs or loud second heart sound can suggest shunt or PH; weak pulses may point to other heart defects. cdt.amegroups.org

3. Spine and limb inspection – looking for vertebral anomalies, scoliosis, missing or hypoplastic thumbs, or radial defects (part of VATER). orpha.net

4. Perineal/anal exam – to identify anal atresia or stenosis early so obstruction is relieved. Children’s Hospital of Philadelphia

5. Airway signs – stridor, wheeze, or barking cough may suggest airway malacia or stenosis, which can raise PH risk via chronic hypoxia. PMC

B) Manual/functional bedside tests and monitoring

6. Pre- and post-ductal oxygen saturation – differences between right hand and foot saturations can signal a shunt or duct-dependent flow. Continuous oximetry also tracks hypoxemia that can drive PH. cdt.amegroups.org

7. Feeding and swallow assessment – bedside observation (and later a formal study) looks for choking or aspiration risk that harms lungs. Children’s Hospital of Philadelphia

8. Blood pressure and growth charting – trends help show heart failure or kidney involvement; poor growth is common in complex VACTERL care. Children’s Hospital of Philadelphia

9. Six-minute walk test (older child/teen) – a simple measure of exercise capacity and PH symptom burden when age-appropriate. publications.ersnet.org

10. Airway endoscopy (flexible bronchoscopy) – a procedural “manual” assessment of airway shape and collapse to diagnose malacia/stenosis that could worsen PH if untreated. PMC

C) Laboratory and pathological tests

11. Arterial/Capillary blood gases – show oxygen and carbon dioxide levels; persistent hypoxemia suggests significant lung/heart disease contributing to PH. cdt.amegroups.org

12. BNP/NT-proBNP – heart strain markers rise with right-ventricular pressure overload in PH and help with monitoring. publications.ersnet.org

13. Renal function tests and urinalysis – screen for kidney anomalies common in VACTERL; renal disease can affect heart and lung treatments. orpha.net

14. Genetic testing panel/exome as indicated – to exclude single-gene syndromes that mimic VACTERL and to look for candidate variants (ZIC3, FOXF1, etc.) that may inform counseling; a negative result does not rule out the association. PMC+1

15. Infection and inflammation labs (CBC, CRP) – recurrent infections from aspiration or airway issues can aggravate lung injury and PH. PMC

D) Electrodiagnostic tests

16. Electrocardiogram (ECG) – looks for right-ventricular hypertrophy, right-axis deviation, or strain patterns seen in PH, and for rhythm problems. It is fast and noninvasive but not definitive. publications.ersnet.org

17. Right-heart catheterization (RHC) – gold standard for diagnosing PH, measuring mPAP, PVR, and wedge pressure to classify PH type and guide therapy; done in expert centers for safety. publications.ersnet.org

E) Imaging tests

18. Transthoracic echocardiography (echo) – first-line tool to screen for PH (estimates right-sided pressures), assess shunts (VSD, PDA), valve function, and right-ventricular size/function. Used repeatedly for follow-up. American College of Cardiology

19. Chest X-ray – quick look at heart size, lung markings, and post-surgical changes; helps detect infections and heart enlargement from PH. cdt.amegroups.org

20. Advanced imaging as needed – CT angiography (airway and vessels), MRI (heart and flow), and V/Q scan (when older, to exclude chronic thromboembolic PH); choice depends on the clinical question and age. Echo screens; RHC confirms. cdt.amegroups.org+1

Non-pharmacological treatments (therapies & others)

1. Specialist-center care and risk-based plan — A PH/PAH center uses a structured algorithm to choose initial therapy, combine drugs, and adjust treatment after follow-up. This reduces hospitalizations and clinical worsening. It is especially important when PH is linked to complex congenital defects, as in VATER-like patterns. publications.ersnet.org+1

2. Supervised exercise / pulmonary rehabilitation — Light-to-moderate, supervised training (walking, cycling, breathing exercises) improves six-minute walk distance, quality of life, and functional class when added to stable PAH therapy. Programs are tailored, avoid symptom-provoking exertion, and monitor oxygen and heart rate. PMC+2internationaljournalofcardiology.com+2

3. Oxygen therapy for hypoxemia — If oxygen levels drop (at rest, sleep, or exertion), low-flow supplemental oxygen supports heart-lung function and may reduce symptoms. Use follows guideline recommendations and individual targets. PubMed+1

4. Diuretic-guided fluid control — When right-heart strain causes fluid buildup, careful use of diuretics (managed by clinicians) plus daily weights, salt awareness, and edema checks helps reduce swelling and breathlessness. This is standard supportive care in PAH. publications.ersnet.org

5. Salt and fluid moderation — Modest sodium restriction and sensible fluid goals lessen edema and make diuretics work better. This aligns with supportive measures in PH care plans. publications.ersnet.org

6. Vaccinations (influenza, pneumococcal, others as advised) — Preventing respiratory infections helps avoid PH decompensation and hospitalizations. PH guidelines routinely recommend age-appropriate immunizations. publications.ersnet.org

7. Sleep and breathing evaluation — Screening for sleep-disordered breathing or hypoventilation (which can worsen PH) and treating it (e.g., CPAP when indicated) improves oxygenation and symptoms. publications.ersnet.org

8. Iron assessment and repletion if deficient — Iron deficiency is common in PAH and linked to worse exercise capacity; checking and correcting deficiency can help symptoms. publications.ersnet.org

9. Pregnancy counseling — Pregnancy can be high-risk in PAH; specialist counseling on contraception and pregnancy risk is essential, especially with endothelin receptor antagonists (which are teratogenic). publications.ersnet.org

10. High-altitude strategy — Plan travel with oxygen assessments; avoid or mitigate high altitude if it causes hypoxemia, which can trigger PH worsening. publications.ersnet.org

11. Anesthesia/sedation planning — Any procedure (including VACTERL-related surgeries) requires PH-aware anesthesia planning to avoid sudden drops in blood pressure or oxygen. Use experienced centers. publications.ersnet.org

12. Psychological support and education — Education about symptom monitoring, safe activity, and early action for infections reduces risk; mental-health support improves adherence and quality of life. publications.ersnet.org

13. Rehabilitation after thoracic/airway repair — When tracheo-esophageal or airway repairs exist, coordinated respiratory therapy helps reduce work of breathing and infections, indirectly easing PH stress. publications.ersnet.org

14. Nutritional counseling — Balanced calories, adequate protein, and micronutrients support energy and recovery; attention to sodium helps edema. Tailor for growth in children with VATER-like features. publications.ersnet.org

15. Infection-prevention routines — Hand hygiene, prompt care for respiratory symptoms, and dental care can prevent triggers of PH exacerbation. publications.ersnet.org

16. Medication safety review — Avoid appetite suppressants or drugs that interact with PAH therapies (e.g., riociguat with PDE-5 inhibitors) and ensure teratogenic drugs use REMS contraception rules. FDA Access Data+1

17. Cardiopulmonary rehab after decompensation — Structured rehabilitation post-hospitalization improves recovery and reduces relapse risk. jtd.amegroups.org

18. Home monitoring — Daily weights, symptom logs, pulse oximetry where appropriate, and early contact with the PH team help catch worsening early. publications.ersnet.org

19. Care coordination across specialties — Because VATER/VACTERL involves multiple systems, integrated follow-up (cardiology, pulmonology, surgery, rehab, nutrition) prevents conflicting plans and gaps. MedlinePlus

20. Early referral for advanced therapies — Timely evaluation for interventional options (septostomy/Potts shunt) or transplant when risk remains high despite drugs improves outcomes. American College of Cardiology

---

Drug treatments

Important: Drug choices and combinations depend on PH type, anatomy, age, and risk. Many agents below are specifically labeled for PAH (WHO Group 1) in adults (some in pediatrics). Dosing below is from FDA labels; clinicians individualize. Do not combine riociguat with PDE-5 inhibitors.

1. Bosentan (Tracleer) — Endothelin receptor antagonist (ERA)
   What/why: Oral dual ERA; improves exercise capacity and delays clinical worsening. Dose/time: Start 62.5 mg twice daily x4 weeks, then 125 mg twice daily (adults). How it works: Blocks endothelin-A/B receptors, reducing vasoconstriction and vascular remodeling in PAH. Common side effects/notes: Liver enzyme elevation (requires monthly LFTs), fluid retention, anemia, teratogenicity; drug interactions via CYP. Use: Foundational therapy alone or in combination in risk-based algorithms. FDA Access Data+1

2. Ambrisentan (Letairis) — ERA
   What/why: Oral selective ETA antagonist; improves exercise ability and delays worsening; in label, can be combined with tadalafil to reduce progression/hospitalization. Dose/time: 5–10 mg once daily. How: Blocks endothelin-A–driven vasoconstriction/remodeling. Side effects: Peripheral edema, nasal congestion, anemia; embryo-fetal toxicity—REMS contraception required. FDA Access Data+2FDA Access Data+2

3. Macitentan (Opsumit) — ERA
   What/why: Long-term ERA that reduces risk of disease progression and PAH hospitalization. Dose/time: 10 mg once daily. How: Dual receptor blockade with high tissue penetration; anti-remodeling effects. Side effects: Anemia, nasopharyngitis, headache; embryo-fetal toxicity—effective contraception required. FDA Access Data

4. Sildenafil (Revatio) — PDE-5 inhibitor
   What/why: Improves exercise ability and delays clinical worsening; oral and IV forms allow continuity during NPO periods. Dose/time: 20 mg orally three times daily; IV 10 mg TID when oral not possible. How: Inhibits PDE-5 → increases cGMP → pulmonary vasodilation and improved hemodynamics. Side effects: Headache, flushing, dyspepsia; caution with nitrates/riociguat; visual changes. FDA Access Data+1

5. Tadalafil (Adcirca) — PDE-5 inhibitor
   What/why: Once-daily option to improve exercise ability; often paired with ambrisentan per label. Dose/time: 40 mg once daily. How: PDE-5 inhibition increases cGMP signaling and vasodilation. Side effects: Headache, myalgia, indigestion; avoid with nitrates/riociguat; dose adjust in renal/hepatic impairment. FDA Access Data+2FDA Access Data+2

6. Riociguat (Adempas) — Soluble guanylate cyclase stimulator
   What/why: For PAH and CTEPH; improves exercise capacity and functional class; do not combine with PDE-5 inhibitors (hypotension risk). Dose/time: Titrate from 1 mg TID (or 0.5 mg if hypotension risk) to max 2.5 mg TID. How: Sensitizes sGC to nitric oxide and directly stimulates it → ↑cGMP → vasodilation and anti-remodeling. Side effects: Hypotension, headache, dyspepsia; embryo-fetal toxicity (REMS). FDA Access Data+2FDA Access Data+2

7. Epoprostenol (Flolan/Veletri) — IV prostacyclin (PGI₂)
   What/why: Gold-standard for high-risk PAH; improves symptoms and survival; continuous IV infusion via pump/central line. Dose/time: Start low and titrate to effect (label-guided protocols). How: Potent vasodilator; inhibits platelet aggregation and smooth-muscle proliferation. Side effects: Flushing, headache, jaw pain, hypotension, catheter complications; bleeding risk from platelet inhibition. FDA Access Data+1

8. Treprostinil (Remodulin) — SC/IV prostacyclin analogue
   What/why: Continuous SC or IV infusion alternative to epoprostenol; improves exercise capacity and delays deterioration; useful for transition strategies. Dose/time: Continuous infusion with individualized titration. How: Prostacyclin pathway agonist → vasodilation/anti-proliferation. Side effects: Infusion site pain (SC), headache, flushing, hypotension. FDA Access Data+2FDA Access Data+2

9. Treprostinil (Tyvaso / Tyvaso DPI) — Inhaled prostacyclin analogue
   What/why: Inhaled dosing delivers pulmonary vasodilation with less systemic hypotension; improves exercise capacity; DPI option available. Dose/time: Multiple inhaled sessions daily per label titration. How: Local prostacyclin pathway activation in lungs. Side effects: Cough, throat irritation, headache; caution in active lung infections. FDA Access Data+2FDA Access Data+2

10. Treprostinil (Orenitram) — Oral extended-release
    What/why: Oral prostacyclin analogue to improve exercise ability and delay progression; sometimes used for transitions. Dose/time: Start low, titrate based on tolerance; several strengths available. How: Systemic prostacyclin pathway activation. Side effects: Headache, nausea, diarrhea; taper gradually if stopping. FDA Access Data+2FDA Access Data+2

11. Iloprost (Ventavis) — Inhaled prostacyclin analogue
    What/why: Short-acting, inhaled PGI₂ analogue given multiple times daily; improves symptoms in selected patients. Dose/time: Frequent inhalations via specific nebulizer per label. How: Potent pulmonary vasodilation; anti-platelet effect (clinical relevance uncertain). Side effects: Cough, flushing, jaw pain; hypotension. FDA Access Data+2FDA Access Data+2

12. Selexipag (Uptravi) — Oral selective prostacyclin-receptor (IP) agonist
    What/why: Add-on oral drug targeting prostacyclin pathway without infusion; reduces PAH progression risk. Dose/time: Titrate in 200 mcg steps to highest tolerated (BID); adjust in hepatic impairment; avoid with strong CYP2C8 inhibitors. Side effects: Headache, jaw pain, nausea, diarrhea. FDA Access Data+2FDA Access Data+2

13. Sotatercept (Winrevair) — Activin signaling inhibitor (novel pathway)
    What/why: First-in-class biologic approved in 2024 for adults with PAH to increase exercise capacity, improve WHO class, and reduce risk of clinical worsening; given SC every 3 weeks with Hgb/platelet monitoring. Dose/time: Start 0.3 mg/kg SC q3 weeks, target 0.7 mg/kg (per label with adjustments for Hgb/platelets). How: Rebalances BMPR2-related signaling by trapping activins → anti-proliferative remodeling benefits beyond vasodilation. Side effects: ↑Hemoglobin, ↓platelets, telangiectasias, bleeding risk; pregnancy avoidance. FDA Access Data+2FDA Access Data+2

14. Calcium channel blockers (only for vasoreactive PAH)
    What/why: A small subset with positive vasoreactivity on catheter testing may benefit; not for non-responders. Dose/time: High-dose amlodipine/nifedipine/diltiazem under specialist supervision. How: Arterial vasodilation reduces pulmonary pressures in responders. Side effects: Edema, hypotension; misuse in non-responders can harm. (Guideline-directed, label not PAH-specific.) publications.ersnet.org

15. Diuretics (supportive)
    What/why: Loop diuretics (e.g., furosemide) ± thiazide/aldosterone antagonist to control fluid overload from right-heart failure. Dose/time: Individualized to edema/renal function. How: Reduces venous congestion and symptoms. Side effects: Electrolyte loss, kidney effects—monitor closely. publications.ersnet.org

16. Digoxin (select patients)
    What/why: Can help right-heart failure or atrial arrhythmias in PAH as supportive therapy. Dose/time: Individualized; monitor levels. How: Increases inotropy and controls rate in AF. Side effects: Arrhythmias, GI symptoms, visual changes. publications.ersnet.org

17. Anticoagulation (case-by-case)
    What/why: Consider when thrombotic risk is high or in specific etiologies; practice varies. Dose/time: Warfarin or DOACs per indication and risk. How: Reduces clot burden; benefits in idiopathic PAH are debated. Side effects: Bleeding; careful selection needed. publications.ersnet.org

18. Iron supplementation (if deficient)
    What/why: Correcting iron deficiency can improve exercise capacity and symptoms. Dose/time: Oral or IV per deficiency and tolerance. How: Supports oxygen transport and muscle function. Side effects: GI upset (oral), infusion reactions (IV). publications.ersnet.org

19. Combination therapy (ERA + PDE-5i ± prostacyclin)
    What/why: Modern standard is early combination to hit multiple pathways; improves outcomes versus monotherapy in appropriate risk tiers. Doses: From individual labels above. How: Targets endothelin, NO-sGC-cGMP, and prostacyclin pathways together. Side effects: Additive headaches, edema, hypotension—monitor. American College of Cardiology+1

20. Bridging with IV/SC prostacyclin
    What/why: For high-risk patients, continuous prostacyclin can stabilize while planning repair of congenital lesions or advanced interventions. How: Strong vasodilator/anti-remodeling effect. Risks: Line infections, hypotension; requires experienced team. FDA Access Data

---

Dietary molecular supplements

(Use only with clinician approval; some interact with PH drugs. Evidence is supportive/adjunctive, not disease-modifying like approved PAH therapies.)

1. Iron (if deficient): Repletes low iron to improve oxygen delivery and exercise tolerance; route and dose depend on labs and tolerance. publications.ersnet.org

2. Vitamin D: Low levels are common in chronic cardiopulmonary disease; repletion supports bone/muscle and immune function; dose per labs. publications.ersnet.org

3. Omega-3 fatty acids: May support endothelial health and inflammation balance; watch for bleeding risk with anticoagulants. publications.ersnet.org

4. Magnesium: Helps muscle and rhythm stability; replace if low, especially with diuretics. publications.ersnet.org

5. Folate/B12 (if low): Corrects anemia contributors and supports red-cell production; dose by deficiency. publications.ersnet.org

6. Beetroot/nitrate sources: Can transiently raise NO availability and ease exertion in some; avoid if interacting drugs/hypotension risk. publications.ersnet.org

7. Coenzyme Q10: Mitochondrial cofactor that may aid fatigue in chronic heart conditions; interactions are possible. publications.ersnet.org

8. L-carnitine: May support muscle energy metabolism; consider if nutritional intake is poor. publications.ersnet.org

9. Zinc (if low): Replace deficiency that can impair immune and wound function; excess can affect copper. publications.ersnet.org

10. Selenium (if low): Deficiency may impair cardiac muscle and antioxidant defense; dose only if deficient. publications.ersnet.org

---

Drugs for immunity booster / regenerative / stem-cell” concepts

There are no approved “immunity-boosting” or stem-cell drugs for PAH. Some experimental or disease-modifying approaches are under study. They should be used only in clinical trials or specialist centers.

1. Sotatercept (Winrevair) — Not a stem cell drug, but a regenerative-pathway modulator; rebalances activin/BMP signaling and is FDA-approved (2024) for adults with PAH to improve capacity and reduce clinical worsening. Dose: 0.3→0.7 mg/kg SC every 3 weeks with blood monitoring. FDA Access Data

2. Cell-based therapies (e.g., endothelial progenitor cells) — Investigational only; small studies explore vascular repair, but safety/benefit remain uncertain; not FDA-approved for PAH. Seek trials at PH centers. publications.ersnet.org

3. Mesenchymal stromal cells (MSCs) — Experimental paracrine anti-inflammatory/anti-fibrotic effects are being studied; use limited to trials. publications.ersnet.org

4. Gene-targeted strategies (BMPR2 pathway) — Early-phase research aims at reversing remodeling; currently not clinical standard. publications.ersnet.org

5. Antioxidant/anti-proliferative nutraceuticals (adjuncts only) — Items like resveratrol/curcumin are studied preclinically; not PAH treatments; avoid interactions. publications.ersnet.org

6. Immunomodulators for specific causes — When PH is linked to connective-tissue disease, immunomodulatory plans may target the underlying disease under rheumatology guidance; this is etiology-specific, not PAH-specific. publications.ersnet.org

---

Surgeries / procedures (what they are, why done)

1. Balloon atrial septostomy (BAS) — A small hole is created between the atria to let blood bypass a failing right heart. It can relieve syncope and low output in refractory PAH or bridge to transplant, but carries risk and must be done at expert centers. PMC+2PMC+2

2. Reverse Potts shunt (left PA–descending aorta) — In selected children with suprasystemic PA pressures, a right-to-left shunt offloads the RV, improves symptoms, and can delay transplant; reinterventions may be needed. Done only in highly specialized centers. Frontiers+2PubMed+2

3. Closure/repair of contributory congenital lesions — Tailored repairs (e.g., certain cardiac shunts) may lower PH drivers; decisions depend on reversibility testing and multidisciplinary evaluation. PMC

4. Lung transplantation — For advanced PAH unresponsive to maximal therapy; single/double lung vs. heart-lung depends on anatomy and hemodynamics; survival has improved with careful selection. PMC+1

5. ECMO as bridge — Short-term support in decompensated PAH while moving to septostomy or transplant in pediatric algorithms. American Thoracic Society

---

Preventions (daily ways to lower risk)

1. Get vaccinated (flu, pneumococcal) to avoid infections that worsen PH. publications.ersnet.org

2. Avoid appetite-suppressant/illicit stimulants linked to PH; review all new meds for interactions. publications.ersnet.org

3. Plan travel/altitude; use oxygen if your team advises. publications.ersnet.org

4. Keep salt modest and track weight to catch fluid retention early. publications.ersnet.org

5. Treat sleep-disordered breathing if present. publications.ersnet.org

6. Follow exercise plans from your PH team; avoid extreme exertion or isometric strain. PMC

7. Adhere to REMS contraception rules with teratogenic drugs (ERAs, riociguat). FDA Access Data+1

8. Keep clinic visits and labs (LFTs with bosentan; Hgb/platelets with sotatercept). FDA Access Data+1

9. Manage anemia and iron deficiency if present. publications.ersnet.org

10. Coordinate care across specialties for VATER-related issues to prevent setbacks. MedlinePlus

---

When to see doctors (or seek urgent care)

• Immediately/ER: new or worsening chest pain, fainting, severe breathlessness at rest, blue lips/skin, fast swelling of legs/abdomen, sudden drop in oxygen, signs of line infection if on infusion therapy. FDA Access Data

• Prompt clinic contact: notable drop in walking ability, new palpitations or dizziness, rising weight/edema over a few days, persistent cough/fever, medication side effects (e.g., jaundice on bosentan; headaches/hypotension on vasodilators). FDA Access Data+1

• Routine follow-up: scheduled risk assessments (walk test, echo, labs), medication checks, contraception counseling where needed. publications.ersnet.org

---

What to eat” and “what to avoid”

• Eat: (1) colorful vegetables and fruits; (2) lean proteins (fish, eggs, legumes); (3) whole grains; (4) healthy fats (olive oil, nuts); (5) potassium-rich foods if not contraindicated; (6) enough protein for growth/repair (children, post-surgery); (7) iron-rich foods if iron-deficient; (8) adequate calcium/vitamin D; (9) ample fluids unless your doctor limits them; (10) small frequent meals if breathless with large meals. publications.ersnet.org

• Avoid/limit: (1) very salty foods (packaged snacks, pickles); (2) heavy alcohol; (3) energy stimulants; (4) grapefruit with some drugs (check labels); (5) crash diets; (6) high-altitude travel without a plan; (7) smoking/vaping; (8) NSAIDs that worsen kidney function with diuretics (ask your team); (9) herbals that interact with PAH meds; (10) unregulated “stem-cell” or “immunity” products. publications.ersnet.org

---

Frequently asked questions (simple answers)

1. Is PAH curable? Not yet, but modern therapies (often in combination) and new agents like sotatercept can significantly improve symptoms and slow worsening; advanced options exist if needed. American College of Cardiology+1

2. Why is VATER-like anatomy relevant? Cardiac/airway defects can contribute to PH; plans must consider the person’s unique anatomy and, when appropriate, reparative surgery. MedlinePlus

3. Can exercise help? Yes—supervised programs improve fitness and quality of life; avoid unsafe exertion. PMC

4. Do I need oxygen? Only if your oxygen level is low at rest, sleep, or exertion—your team will test and set targets. PubMed

5. Which drug class is “best”? Best therapy depends on risk, age, and response; many patients start with combination therapy targeting multiple pathways. American College of Cardiology

6. Can I take riociguat with sildenafil/tadalafil? No. This is contraindicated due to hypotension risk. FDA Access Data

7. Are ERAs safe in pregnancy? No—ERAs are teratogenic; strict contraception and REMS apply. FDA Access Data

8. What if I’m getting worse on pills? High-risk patients are often escalated to IV/SC prostacyclin or evaluated for septostomy/transplant. FDA Access Data

9. Does iron matter? Iron deficiency can worsen exercise tolerance; checking and treating it can help. publications.ersnet.org

10. What is sotatercept? A new injectable that rebalances growth-factor signaling; improves exercise capacity and reduces clinical worsening in adults with PAH. FDA Access Data

11. Are stem-cell therapies available? Not as approved treatments; consider only within regulated clinical trials. publications.ersnet.org

12. Can surgery fix PH? Some congenital lesions can be repaired after careful testing; for refractory PAH, BAS/Potts or transplant may be options at expert centers. PMC+1

13. Why so many blood tests? Some drugs need monitoring (e.g., liver tests with bosentan; Hgb/platelets with sotatercept) to stay safe. FDA Access Data+1

14. Is anticoagulation routine? It’s individualized; benefits and bleeding risks are weighed per patient. publications.ersnet.org

15. Who should coordinate my care? A PH center familiar with VATER/VACTERL and congenital heart disease should lead, coordinating pulmonology, cardiology, surgery, rehab, and nutrition. MedlinePlus

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 02, 2025.